ADVERTISEMENT

404

Not Found

Is this what you were looking for?

magazine issue in editing rna researchers see endless possibilitiesrna editors are catching up to crispr cas9

A close up of a tick held in a pair of forceps, with Kevin Esvelt’s face out of focus in the background.
CRISPR Gene Drives and the Future of Evolution
Hannah Thomasy, PhD | Mar 15, 2024 | 10+ min read
Genetic engineering pioneer Kevin Esvelt’s work highlights biotechnology’s immense potential for good—but also for catastrophe.
Two hands cut and manipulate the genome surrounded by different organs of interest.
The Cre-loxP System: A Powerful Tool in the Genetic Toolbox
Laura Tran, PhD | Dec 4, 2023 | 9 min read
Standing at the cornerstone of genetic research, Cre-loxP recombination serves as molecular scissors for precisely manipulating the genome.
Illustration of DNA
Can “Gene Writing” Deliver What Gene Editing Can’t?
Dan Robitzski | Dec 12, 2022 | 10+ min read
A biotech startup called Tessera Therapeutics has made a splash with its claims about the trademarked technology. Is the excitement justified?
DNA
In Editing RNA, Researchers See Endless Possibilities
Christie Wilcox, PhD | Dec 1, 2021 | 10 min read
RNA editing has been in DNA editing’s shadow for nearly a decade, but recent investments in the technology could bring it into the limelight.
an illustration of Toxoplasma gondii parasites infecting cells
Top Technical Advances of 2019
Shawna Williams | Dec 24, 2019 | 3 min read
From artificial intelligence to pluripotent stem cells, this year saw the publication of a bevy of intriguing new methods, as well as tweaks to existing protocols.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Was a Drop in CRISPR Firms’ Stock Warranted?
Claire Asher | Jun 7, 2017 | 4 min read
A study of off-target effects that sparked fear among investors of genome-editing companies receives methodological criticisms.
RNAi’s Future in Drug-Target Screening
Catherine Offord | Apr 16, 2017 | 4 min read
A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 
2018 Top 10 Innovations
The Scientist | Dec 1, 2018 | 10+ min read
Biology happens on many levels, from ecosystems to electron transport chains. These tools may help spur discoveries at all of life's scales.
2017 Top 10 Innovations
The Scientist | Dec 1, 2017 | 10+ min read
From single-cell analysis to whole-genome sequencing, this year's best new products shine on many levels.

Run a Search

ADVERTISEMENT